These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 7739653)

  • 1. Prophylaxis of Candida and Aspergillus infections with oral administration of itraconazole.
    Van Cutsem J
    Mycoses; 1994; 37(7-8):243-8. PubMed ID: 7739653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activities of an intravenous formulation of itraconazole in experimental disseminated Aspergillus, Candida, and Cryptococcus infections.
    Odds FC; Oris M; Van Dorsselaer P; Van Gerven F
    Antimicrob Agents Chemother; 2000 Nov; 44(11):3180-3. PubMed ID: 11036047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapy of experimental meningeal and disseminated cryptococcosis.
    Van Cutsem J
    Mycoses; 1993; 36(11-12):357-67. PubMed ID: 7935566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro antifungal spectrum of itraconazole and treatment of systemic mycoses with old and new antimycotic agents.
    Van Cutsem J
    Chemotherapy; 1992; 38 Suppl 1():3-11. PubMed ID: 1319313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral itraconazole therapy for superficial, subcutaneous, and systemic infections. A panoramic view.
    De Rosso JQ; Gupta AK
    Postgrad Med; 1999 Jul; Spec No():46-52. PubMed ID: 10492666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Itraconazole in neutropenic patients.
    van't Wout JW
    Chemotherapy; 1992; 38 Suppl 1():23-6. PubMed ID: 1319311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fungal colonization in neutropenic patients: a randomized study comparing itraconazole solution and amphotericin B solution.
    Lass-Flörl C; Gunsilius E; Gastl G; Englisch M; Koch G; Ulmer H; Dierich MP; Petzer A
    Ann Hematol; 2003 Sep; 82(9):565-9. PubMed ID: 14504812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Guideline: vulvovaginal candidosis (AWMF 015/072), S2k (excluding chronic mucocutaneous candidosis).
    Mendling W; Brasch J; Cornely OA; Effendy I; Friese K; Ginter-Hanselmayer G; Hof H; Mayser P; Mylonas I; Ruhnke M; Schaller M; Weissenbacher ER
    Mycoses; 2015 Mar; 58 Suppl 1():1-15. PubMed ID: 25711406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. European experience with oral solution and intravenous itraconazole.
    Potter M
    Oncology (Williston Park); 2001 Nov; 15(11 Suppl 9):27-32. PubMed ID: 11757848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [In-vitro and in-vivo activity of itraconazole].
    Van Cutsem J
    Med Klin (Munich); 1991 Dec; 86 Suppl 1():5-8. PubMed ID: 1663204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prophylaxis against mycoses in neutropenic patients].
    Arning M; Aul C
    Mycoses; 1994; 37 Suppl 2():70-6. PubMed ID: 7541892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful bone marrow transplantation in patients with previous invasive fungal infections: report of four cases.
    Martino R; Nomdedéu J; Altés A; Sureda A; Brunet S; Martínez C; Domingo-Albós A
    Bone Marrow Transplant; 1994 Mar; 13(3):265-9. PubMed ID: 8199569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: surveillance of multicenter antimicrobial resistance in Taiwan program data from 2003.
    Hsueh PR; Lau YJ; Chuang YC; Wan JH; Huang WK; Shyr JM; Yan JJ; Yu KW; Wu JJ; Ko WC; Yang YC; Liu YC; Teng LJ; Liu CY; Luh KT
    Antimicrob Agents Chemother; 2005 Feb; 49(2):512-7. PubMed ID: 15673726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Strategies for managing systemic fungal infection and the place of itraconazole.
    Potter M
    J Antimicrob Chemother; 2005 Sep; 56 Suppl 1():i49-i54. PubMed ID: 16120634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical antimycotic activity of SDZ 89-485: a new orally and topically effective triazole.
    Schaude M; Petranyi G; Ackerbauer H; Meingassner JG; Mieth H
    J Med Vet Mycol; 1990; 28(6):445-54. PubMed ID: 2093117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and mycological efficacy of single-day oral treatment with itraconazole (400 mg) in acute vulvovaginal candidosis.
    Urünsak M; Ilkit M; Evrüke C; Urünsak I
    Mycoses; 2004 Oct; 47(9-10):422-7. PubMed ID: 15504127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A double-blind, randomized, placebo-controlled trial of itraconazole capsules as antifungal prophylaxis for neutropenic patients.
    Nucci M; Biasoli I; Akiti T; Silveira F; Solza C; Barreiros G; Spector N; Derossi A; Pulcheri W
    Clin Infect Dis; 2000 Feb; 30(2):300-5. PubMed ID: 10671332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of invasive fungal infections in patients with neoplastic disease.
    Walsh TJ; Lee JW
    Clin Infect Dis; 1993 Nov; 17 Suppl 2():S468-80. PubMed ID: 8274613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Experimental aspergillosis in guinea pigs: influence of itraconazole on fungaemia and invasive fungal growth.
    Arrese JE; Delvenne P; Van Cutsem J; Piérard-Franchimont C; Piérard GE
    Mycoses; 1994; 37(3-4):117-22. PubMed ID: 7845416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antifungal prophylaxis in neutropenic patients with hematologic malignancies.
    Böhme A; Karthaus M; Hoelzer D
    Antibiot Chemother (1971); 2000; 50():69-78. PubMed ID: 10874456
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.